1. Home
  2. BEAM vs VVX Comparison

BEAM vs VVX Comparison

Compare BEAM & VVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BEAM
  • VVX
  • Stock Information
  • Founded
  • BEAM 2017
  • VVX 2014
  • Country
  • BEAM United States
  • VVX United States
  • Employees
  • BEAM N/A
  • VVX N/A
  • Industry
  • BEAM Biotechnology: Biological Products (No Diagnostic Substances)
  • VVX Diversified Commercial Services
  • Sector
  • BEAM Health Care
  • VVX Consumer Discretionary
  • Exchange
  • BEAM Nasdaq
  • VVX Nasdaq
  • Market Cap
  • BEAM 1.6B
  • VVX 1.4B
  • IPO Year
  • BEAM 2020
  • VVX 2014
  • Fundamental
  • Price
  • BEAM $21.16
  • VVX $49.21
  • Analyst Decision
  • BEAM Strong Buy
  • VVX Buy
  • Analyst Count
  • BEAM 11
  • VVX 9
  • Target Price
  • BEAM $48.90
  • VVX $64.11
  • AVG Volume (30 Days)
  • BEAM 2.2M
  • VVX 251.1K
  • Earning Date
  • BEAM 08-05-2025
  • VVX 08-04-2025
  • Dividend Yield
  • BEAM N/A
  • VVX N/A
  • EPS Growth
  • BEAM N/A
  • VVX N/A
  • EPS
  • BEAM N/A
  • VVX 1.29
  • Revenue
  • BEAM $63,578,000.00
  • VVX $4,327,514,000.00
  • Revenue This Year
  • BEAM N/A
  • VVX $4.02
  • Revenue Next Year
  • BEAM $17.18
  • VVX $4.80
  • P/E Ratio
  • BEAM N/A
  • VVX $38.10
  • Revenue Growth
  • BEAM N/A
  • VVX 7.38
  • 52 Week Low
  • BEAM $13.53
  • VVX $41.08
  • 52 Week High
  • BEAM $35.25
  • VVX $69.75
  • Technical
  • Relative Strength Index (RSI)
  • BEAM 65.49
  • VVX 58.54
  • Support Level
  • BEAM $19.02
  • VVX $48.84
  • Resistance Level
  • BEAM $22.51
  • VVX $50.29
  • Average True Range (ATR)
  • BEAM 1.15
  • VVX 1.22
  • MACD
  • BEAM 0.49
  • VVX 0.26
  • Stochastic Oscillator
  • BEAM 78.91
  • VVX 76.55

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

About VVX V2X Inc.

V2X Inc is a U.S.-based company that provides services to the U.S. government. It operates as one segment and offers facility and logistics services and information technology mission support and engineering and digital integration services. The information technology and network communications capabilities consist of communications systems operations and maintenance, management and service support, systems installation and activation, system-of-systems engineering and software development, and mission support for the department of defense. The facility and logistics service include airfield management, ammunition management, civil engineering, communications, emergency services, life support activities, public works, security, transportation operations, and others.

Share on Social Networks: